HGS HGS has a well balanced and deep portfolio of novel drugs directed toward diseases that represent significant unmet medical need. Three of these products are in late-stage development.

In March 2009 and December 2008, we reported positive Phase 3 results from our Phase 3 trials of Albuferon® (albinterferon alfa-2b) in patients with chronic hepatitis C. Filings of global marketing applications are planned in fall 2009. Two Phase 3 trials are ongoing for BENLYSTA™ (belimumab, formerly LymphoStat-B®) in patients with systemic lupus erythematosus (SLE), with results expected in July and November 2009. Raxibacumab (ABthrax™) is in late-stage development for the treatment of inhalation anthrax.

Right behind these late-stage products is an emerging high-potential mid-stage pipeline, led by our anti-cancer products, HGS-ETR1 (mapatumumab) and HGS 1029, an IAP inhibitor – both for the treatment of cancer. We also have substantial financial rights to a number of products in the GlaxoSmithKline clinical pipeline. GSK has initiated Phase 3 clinical trials of darapladib in men and women with chronic coronary heart disease, and Syncria® (albiglutide) in patients with type 2 diabetes mellitus.
.

	NAME	INDICATION	PHASE 1	PHASE 2	PHASE 3
	Albuferon	Hepatitis C
	BENLYSTA*	SLE
	Raxibacumab	Anthrax
	HGS-ETR1	Cancer
	HGS1029	Cancer
	BENLYSTA*	Additional Autoimmune
	Darapladib	Heart Disease
	Syncria®	Diabetes

*belimumab, formerly LymphoStat-B